Clinical Trials Logo

Filter by:
NCT ID: NCT05265364 Active, not recruiting - Radiation Toxicity Clinical Trials

Acute Toxicity After Moderate Hypo-fractionated Intensity Modulated Radiotherapy IMRT or Prostate Cancer

Start date: July 25, 2022
Phase:
Study type: Observational

External radiation techniques (EBRT) is considered one of the primary therapies for patients of all risk classifications of prostate cacer . EBRT aims to control tumor growth while keeping acute and late adverse events to a minimum and ensuring biochemical progression-free outcome

NCT ID: NCT05264961 Active, not recruiting - Dysphonia Clinical Trials

Behavioral Abnormalities in Dysphonic Children

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

we will assess dysphonic children as regard presence of behavioral abnormalities and then receive voice therapy

NCT ID: NCT05260944 Active, not recruiting - Clinical trials for Coronary Artery Bypass Graft Surgery

Power Lung Versus Acapella After Coronary Artery Bypass Graft Surgery

Start date: August 5, 2021
Phase: N/A
Study type: Interventional

The purpose of the study is to compare between the power lung versus acapella on airway clearance after coronary artery bypass graft surgery.

NCT ID: NCT05260593 Active, not recruiting - Clinical trials for Carpal Tunnel Syndrome

Effect of Phonophoresis With Vitamin B12 on CTS

Start date: March 16, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to investigate efficacy of phonophoresis with vitamin B12 on median nerve distal latency, pain level and hand grip strength in patients with carpal tunnel syndrome. At least Fifty four Patients from both sexes will be recruited for this study from various hospitals in 6th October city - Group A (n = 27): will receive Phonophoresis with Vitamin B12 gel. - Group B (n = 27): will receive placebo phonophoresis with Vitamin B12 gel. Median nerve distal latency, hand grip strength and numerical pain rating scale will be measured at baseline and after 3 weeks.

NCT ID: NCT05254626 Active, not recruiting - Clinical trials for Non-alcoholic Steatohepatitis

Efficacy and Safety of Dapagliflozin in Patients With Non-alcoholic Steatohepatitis

Start date: August 1, 2022
Phase: Phase 2
Study type: Interventional

Patients with non-alcoholic fatty liver disease (NAFLD) are at increased risk of more aggressive liver disease; non-alcoholic steatohepatitis (NASH) and at a higher risk of death from cirrhosis, hepatocellular carcinoma and cardiovascular diseases. NAFLD is spreading as an epidemic in patients with metabolic syndrome. Its components include obesity, type 2 diabetes mellitus (T2DM) and dyslipidemia. The prevalence of NAFLD is likely to increase resulting in tremendous clinical, social and economic burdens. Unfortunately, there is no approved medication to treat patients with NASH-induced advanced fibrosis. Weight management is the first line of NASH treatment even in non-obese patients with at least 7% reduction of patient's weight. However, NASH patients need pharmacological treatment. Sodium glucose co-transporter (SGLT2) inhibitors demonstrated favorable effects on NAFLD without weight gain as an adverse event proposed by pioglitazone used for the same indication. SGLT2 inhibitors are able to reduce fatty liver content, as assessed by different imaging techniques, and improve biological markers of NAFLD, especially serum liver enzymes, in patients with or without T2DM. In addition, there are emerging data to suggest a mechanism beyond the reduction of body weight and hyperglycemia in patients with or without diabetes. This study aims to evaluate the efficacy and safety of SGLT2 inhibitors in NASH patients in comparison to pioglitazone. This is a randomized prospective parallel study, where all patients presented with NASH to the outpatient clinic in the National Hepatology and Tropical Medicine Research Institute, Cairo, Egypt; will be screened for specific inclusion and exclusion criteria. Diabetic and non-diabetic patients will be randomly assigned to receive one of two treatment modalities. The first arm will be the NASH patients receiving dapagliflozin and the second arm will be the NASH patients receiving pioglitazone for 24 weeks. Each group will have an equal number of diabetic and non-diabetic patients. All patients will be assessed for body composition, serum creatinine level, fasting blood glucose level, HbA1C, markers of insulin resistance (HOMA-IR), complete blood count, serum liver function tests, and NAFLD fibrosis score (NAS). Liver biopsy will be performed at baseline and at the end of the study and the total NAS score will be calculated. All patients will be assessed for any adverse drug reactions, and for their adherence by pill count method. Also, quality of life will be assessed for all patients using previously designed and validated questionnaire called Chronic Liver Disease Questionnaire (CLDQ).

NCT ID: NCT05234619 Active, not recruiting - Clinical trials for Hand Injuries With Intravenous Regional Anesthesia

Early Versus Late Deflation of Distal Tourniquet in IVRA With and Without Ketorolac in Hand & Forearm Surgery

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Bier block , or intravenous regional anesthesia (IVRA), is a method of anesthesia for upper extremity surgeries. IVRA was first described by August Bier in 1908, and after a period of latency, it began to gain widespread use after Holmes reemphasized its use in 1963. Bier blocks are technically easy to perform, and the rates for successful anesthesia approach 98%. Furthermore, when compared with brachial plexus blocks for outpatient hand and upper extremity surgery, IVRA may realize lower costs and faster postanesthesia recovery. Although a reliable source of anesthesia, IVRA has been associated with some disadvantages. Some patients cannot tolerate the tourniquet-mediated arm pain, and there are also reports of neurologic injury and compartment syndrome caused by the tourniquet. Perhaps the most serious complications associated with IVRA relate to the potential systemic toxicity of the local anesthetics used. If the local anesthetic gains access to a patient's systemic circulation, the central nervous system (CNS) and cardiovascular system can be affected. The CNS is usually affected first, with symptoms including dizziness, tinnitus, perioral paresthesia, and seizures. Anesthetic-induced toxicity of the cardiovascular system may manifest as hypotension, bradycardia, arrhythmias, or cardiac arrest. Historically, the tourniquet used in IVRA is left inflated for a minimum of 20 minutes. Theoretically, this allows time for the local anesthetic to bind to the tissues and, consequently, prevent a large bolus of drug from entering the systemic circulation. However, this tourniquet time appears to be arbitrary, and no safe time interval between anesthetic drug injection and tourniquet deflation has been established.

NCT ID: NCT05230316 Active, not recruiting - SLE Clinical Trials

Gynecological Symptoms and Health-related Quality of Life in Egyptian Women With SLE

Start date: January 15, 2022
Phase:
Study type: Observational

The purpose of our study was to Recognize gynecological symptoms and health-related quality of life in Egyptian women with systemic lupus erythematosus and evaluate the impact of duration of remission on QOL in SLE patients.

NCT ID: NCT05223738 Active, not recruiting - Vitiligo Clinical Trials

Resident Memory T Cells in Vitiligo

Start date: December 31, 2020
Phase:
Study type: Observational

This study aims to detect the presence and diversity of Tissue resident memory T cell populations in early and late cases of generalized non-segmental Vitiligo.

NCT ID: NCT05223075 Active, not recruiting - Pain Clinical Trials

Articaine Versus Lidocaine Buccal Infiltration

Start date: November 11, 2022
Phase: Phase 2
Study type: Interventional

assess the effect of articaine versus lidocaine in only buccal infiltration of local anethesia in lower anterior teeth

NCT ID: NCT05221684 Active, not recruiting - Recurrence Clinical Trials

Lymph Node Ratio as a Predictor for Outcome in Rectal Cancer

Start date: June 9, 2020
Phase:
Study type: Observational

This study aims to evaluate the value of the LNR as a prognostic indicator in patients with rectal cancer who offered total mesorectal excision.